1. Thingore C, Kshirsagar V, Juvekar A. Amelioration of oxidative stress and neuroinflammation in lipopolysaccharide-induced memory impairment using rosmarinic acid in mice. Metab Brain Dis 2021;36:299–313.
2. Congdon EE, Ji C, Tetlow AM, Jiang Y, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease: Current status and future directions. Nat Rev Neurol 2023;19:715–736.
3. Shim KH, Kang MJ, Youn YC, An SSA, Kim S. Alpha-synuclein: a pathological factor with Aβ and tau and biomarker in Alzheimer’s disease. Alzheimers Res Ther 2022;14:201.
4. Vaz M, Silvestre S. Alzheimer’s disease: Recent treatment strategies. Eur J Pharmacol 2020;887:173554.
5. Lista S, Vergallo A, Teipel SJ, Lemercier P, Giorgi FS, Gabelle A, et al. Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimer’s disease: Relevance for precision medicine in neurodegenerative diseases. Ageing Res Rev 2023;84:101819.
6. Holtzman DM, Carrillo MC, Hendrix JA, Bain LJ, Catafau AM, Gault LM, et al. Tau: From research to clinical development. Alzheimer’s Dement. 2016;12:1033–1039.
7. Noble W, Hanger DP, Miller CCJ, Lovestone S. The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol 2013;4:83.
8. Mandelkow E-M, Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med 2012;2:a006247.
9. Twohig D, Nielsen HM. α-synuclein in the pathophysiology of Alzheimer’s disease. Mol Neurodegener 2019;14:1–19.
10. Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: The balancing act of BCL-2 family proteins. Nat Rev Mol cell Biol 2019;20:175–193.
11. Sharma VK, Singh TG, Singh S, Garg N, Dhiman S. Apoptotic pathways and Alzheimer’s disease: Probing therapeutic potential. Neurochem Res 2021;46:3103–3122.
12. Radi E, Formichi P, Battisti C, Federico A. Apoptosis and oxidative stress in neurodegenerative diseases. J Alzheimer’s Dis 2014;42:S125–S152.
13. Habtemariam S. Natural products in Alzheimer’s disease therapy: would old therapeutic approaches fix the broken promise of modern medicines? Molecules 2019;24:1519.
14. Andrade JM, Faustino C, Garcia C, Ladeiras D, Reis CP, Rijo P. Rosmarinus officinalis L.: An update review of its phytochemistry and biological activity. Futur Sci OA 2018;4:FSO283.
15. Khamse S, Sadr SS, Roghani M, Hasanzadeh G, Mohammadian M. Rosmarinic acid exerts a neuroprotective effect in the kainate rat model of temporal lobe epilepsy: Underlying mechanisms. Pharm Biol 2015;53:1818–1825.
16. Kondo S, El Omri A, Han J, Isoda H. Antidepressant-like effects of rosmarinic acid through mitogen-activated protein kinase phosphatase-1 and brain-derived neurotrophic factor modulation. J Funct Foods 2015;14:758–766.
17. Palakurti R, Vadrevu R. Identification of abelson tyrosine kinase inhibitors as potential therapeutics for Alzheimer’s disease using multiple e-pharmacophore modeling and molecular dynamics. J Biomol Struct Dyn 2017;35:883–896.
18. Hebron ML, Lonskaya I, Moussa CE-H. Tyrosine kinase inhibition facilitates autophagic SNCA/α-synuclein clearance. Autophagy 2013;9:1249–1250.
19. Schlatterer SD, Acker CM, Davies P. c-Abl in neurodegenerative disease. J Mol Neurosci 2011;45:445–452.
20. Tremblay MA, Acker CM, Davies P. Tau phosphorylated at tyrosine 394 is found in Alzheimer’s disease tangles and can be a product of the Abl-related kinase, Arg. J Alzheimer’s Dis 2010;19:721–733.
21. Han X, Han B, Zhao Y, Li G, Wang T, He J, et al. Rosmarinic acid attenuates rotenone-induced neurotoxicity in sh-sy5y parkinson’s disease cell model through abl inhibition. Nutrients 2022;14:3508.
22. Rehfeldt SCH, Silva J, Alves C, Pinteus S, Pedrosa R, Laufer S, et al. Neuroprotective effect of luteolin-7-O-glucoside against 6-OHDA-induced damage in undifferentiated and RA-differentiated SH-SY5Y cells. Int J Mol Sci 2022;23:2914.
23. Eroğlu Güneş C, Güçlü E, Vural H, Kurar E. Knockdown of lncRNA ZEB2NAT suppresses epithelial mesenchymal transition, metastasis and proliferation in breast cancer cells. Gene 2021;805:145904.
24. Yang M, Zhang X, Qiao O, Ji H, Zhang Y, Han X, et al. Rosmarinic acid potentiates and detoxifies tacrine in combination for Alzheimer’s disease. Phytomedicine 2023;109:154600.
25. Gülçin İ, Scozzafava A, Supuran CT, Koksal Z, Turkan F, Çetinkaya S, et al. Rosmarinic acid inhibits some metabolic enzymes including glutathione S-transferase, lactoperoxidase, acetylcholinesterase, butyrylcholinesterase and carbonic anhydrase isoenzymes. J Enzyme Inhib Med Chem 2016;31:1698–1702.
26. Ferlemi A-V, Katsikoudi A, Kontogianni VG, Kellici TF, Iatrou G, Lamari FN, et al. Rosemary tea consumption results to anxiolytic- and anti-depressant-like behavior of adult male mice and inhibits all cerebral area and liver cholinesterase activity; phytochemical investigation and in silico studies. Chem Biol Interact 2015;237:47–57.
27. Šebestík J, Marques SM, Falé PL, Santos S, Arduíno DM, Cardoso SM, et al. Bifunctional phenolic-choline conjugates as anti-oxidants and acetylcholinesterase inhibitors. J Enzyme Inhib Med Chem 2011; 26:485–497.
28. El Omri A, Han J, Yamada P, Kawada K, Abdrabbah M Ben, Isoda H. Rosmarinus officinalis polyphenols activate cholinergic activities in PC12 cells through phosphorylation of ERK1/2. J Ethnopharmacol 2010;131:451–458.
29. Mushtaq N, Schmatz R, Pereira LB, Ahmad M, Stefanello N, Vieira JM, et al. Rosmarinic acid prevents lipid peroxidation and increase in acetylcholinesterase activity in brain of streptozotocin‐induced diabetic rats. Cell Biochem Funct 2014;32:287–293.
30. Ozarowski M, Mikolajczak PL, Bogacz A, Gryszczynska A, Kujawska M, Jodynis-Liebert J, et al. Rosmarinus officinalis L. leaf extract improves memory impairment and affects acetylcholinesterase and butyrylcholinesterase activities in rat brain. Fitoterapia 2013;91:261–271.
31. Kola A, Hecel A, Lamponi S, Valensin D. Novel perspective on Alzheimer’s disease treatment: Rosmarinic acid molecular interplay with copper (II) and amyloid β. Life 2020;10:118.
32. Hamaguchi T, Ono K, Murase A, Yamada M. Phenolic compounds prevent alzheimer’s pathology through different effects on the amyloid-β aggregation pathway. Am J Pathol 2009;175:2557–2565.
33. Lee AY, Hwang BR, Lee MH, Lee S, Cho EJ. Perilla frutescens var. japonica and rosmarinic acid improve amyloid-β25-35 induced impairment of cognition and memory function. Nutr Res Pract 2016;10:274–281.
34. Cornejo A, Aguilar Sandoval F, Caballero L, Machuca L, Muñoz P, Caballero J, et al. Rosmarinic acid prevents fibrillization and diminishes vibrational modes associated to β sheet in tau protein linked to Alzheimer’s disease. J Enzyme Inhib Med Chem 2017;32:945–953.
35. Rahman MA, Rahman MDH, Biswas P, Hossain MS, Islam R, Hannan MA, et al. Potential therapeutic role of phytochemicals to mitigate mitochondrial dysfunctions in Alzheimer’s disease. Antioxidants 2021; 10: 23.
36. de Medeiros LM, De Bastiani MA, Rico EP, Schonhofen P, Pfaffenseller B, Wollenhaupt-Aguiar B, et al. Cholinergic differentiation of human neuroblastoma SH-SY5Y cell line and its potential use as an in vitro model for Alzheimer’s disease studies. Mol Neurobiol 2019;56:7355–7367.
37. Agholme Lotta, Lindström Tobias, Kågedal Katarina, Marcusson Jan, Hallbeck Martin. An in vitro model for neuroscience: Differentiation of SH-SY5Y cells into cells with morphological and biochemical characteristics of mature neurons. J Alzheimer’s Dis 2010;20:1069–1082.
38. Yamamoto S, Kayama T, Noguchi-Shinohara M, Hamaguchi T, Yamada M, Abe K, et al. Rosmarinic acid suppresses tau phosphorylation and cognitive decline by downregulating the JNK signaling pathway. NPJ Sci Food 2021;5:1.
39. Iuvone T, De Filippis D, Esposito G, D’Amico A, Izzo AA. The spice sage and its active ingredient rosmarinic acid protect PC12 cells from amyloid-β peptide-induced neurotoxicity. J Pharmacol Exp Ther 2006;317:1143–1149.
40. Ueda K, Fukushima H, Masliah E, Xia YU, Iwai A, Yoshimoto M, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci 1993;90:11282–11286.
41. Masliah E, Iwai A, Mallory M, Uéda K, Saitoh T. Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer’s disease. Am J Pathol 1996;148:201.
42. Milà-Alomà M, Salvadó G, Gispert JD, Vilor-Tejedor N, Grau-Rivera O, Sala-Vila A, et al. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer’s continuum. Alzheimer’s Dement 2020;16:1358–1371.
43. Larson ME, Sherman MA, Greimel S, Kuskowski M, Schneider JA, Bennett DA, et al. Soluble α-synuclein is a novel modulator of Alzheimer’s disease pathophysiology. J Neurosci 2012;32:10253–10266.
44. Keskin E, Gezen-Ak D, Dursun E. Amyloid β,α-synuclein and amyloid β-α-synuclein combination exert significant but different alterations in inflammatory response profile in differentiated human SH-SY5Y cells. ACS Omega 2023;8:45519–45534.
45. Ogawa K, Ishii A, Shindo A, Hongo K, Mizobata T, Sogon T, et al. Spearmint extract containing rosmarinic acid suppresses amyloid fibril formation of proteins associated with dementia. Nutrients 2020;12:3480.
46. Schlatterer SD, Tremblay MA, Acker CM, Davies P. Neuronal c-Abl overexpression leads to neuronal loss and neuroinflammation in the mouse forebrain. J Alzheimer’s Dis 2011;25:119–133.
47. Hebron ML, Lonskaya I, Olopade P, Selby ST, Pagan F, Moussa CEH. Tyrosine kinase inhibition regulates early systemic immune changes and modulates the neuroimmune response in α-synucleinopathy. J Clin Cell Immunol 2014;5:259.
48. Vargas LM, Cerpa W, Muñoz FJ, Zanlungo S, Alvarez AR. Amyloid-β oligomers synaptotoxicity: The emerging role of EphA4/c-Abl signaling in Alzheimer’s disease. Biochim Biophys Acta Mol Basis Dis 2018;1864:1148–1159.
49. Gutierrez DA, Vargas LM, Chandia-Cristi A, De la Fuente C, Leal N, Alvarez AR. c-Abl deficiency provides synaptic resiliency against Aβ-oligomers. Front Cell Neurosci 2019;13:526.
50. Brahmachari S, Ge P, Lee SH, Kim D, Karuppagounder SS, Kumar M, et al. Activation of tyrosine kinase c-Abl contributes to α-synuclein–induced neurodegeneration. J Clin Invest 2016;126:2970-2988.
51. Zhu Q, Chen J, Wu X, Jin X, Ruan B. Repurposing of kinase inhibitors to target c-abl as potential therapeutics for alzheimer’s disease. J Pharm Innov 2014;9:331-340.
52. Pardridge WM. Alzheimer’s disease drug development and the problem of the blood-brain barrier. Alzheimer’s Dement 2009;5:427-432.
53. Senior K. Gleevec does not cross blood–brain barrier. Lancet Oncol 2003;4:198.
54. Blay J-Y, von Mehren M. Nilotinib: A novel, selective tyrosine kinase inhibitor. In: Seminars in oncology. Elsevier 2011; S3-S9.
55. Porkka K, Koskenvesa P, Lundán T, Rimpiläinen J, Mustjoki S, Smykla R, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia. Blood, J Am Soc Hematol 2008;112:1005-1012.
56. Chi H, Chang H-Y, Sang T-K. Neuronal cell death mechanisms in major neurodegenerative diseases. Int J Mol Sci 2018;19:3082.
57. Ekundayo BE, Obafemi TO, Adewale OB, Obafemi BA, Oyinloye BE, Ekundayo SK. Oxidative stress, endoplasmic reticulum stress and apoptosis in the pathology of Alzheimer’s disease. Cell Biochem Biophys 2024;82, 457-477.
58. Mirza FJ, Zahid S. Ursolic acid and rosmarinic acid ameliorate alterations in hippocampal neurogenesis and social memory induced by amyloid beta in mouse model of Alzheimer’s disease. Front Pharmacol 2022;13:1058358.
)